Jefferies remains optimistic about Abiomed

Analysts are expressing optimism over Abiomed (NSDQ:ABMD) after the company’s third-quarter results saw its stock soar yesterday.

Upon releasing the quarterly report, Abiomed’s stock rose 12.4% at $369.45 in the early morning yesterday. The stock price rose as high as $387.23 yesterday but has since dropped to $341.42 at midday today.

Jefferies analysts released a report highlighting the long-term growth prospects for Abiomed’s Impella heart pump for high-risk percutaneous coronary intervention (PCI) and the strength of the company’s position as it navigates through the COVID-19 pandemic.

Even with COVID-19-related headwinds, Abiomed offered improved guidance for revenue growth between 9% and 14% in the fourth quarter, leading the analysts to feel bullish about the company’s prospects and list it as a “buy” option.

Additionally, analysts are buoyed by Abiomed’s reports of ahead-of-schedule technologi…

Read more
  • 0

Hologic says revenue nearly doubled in Q1

Hologic (NSDQ:HOLX) announced today that its revenues nearly doubled year-over-year in the first quarter of fiscal 2021.

Marlborough, Mass.-based Hologic expects to report revenues of more than approximately $1.6 billion, an increase of 89.3% from the first quarter of 2020. That tops the company’s November guidance of between $1.35 billion and $1.425 billion for the quarter ended Dec. 26, 2020, according to a news release.

“Hologic’s strong momentum continued in the first quarter of fiscal 2021 as organic revenue more than doubled, well ahead of our prior expectations,” Hologic chairman, president & CEO Steve MacMillan said in the release. “Thanks to the incredible efforts of our diagnostics team, we provided almost 30 million COVID-19 tests to global customers in the quarter. Importantly as well, our breast Health and surgical businesses showed remarkable strength, with each franchise posting growth in all major geographies – the United States, Europ…

Read more
  • 0

TAVR sales growth was flat in July, Jefferies reports

Edwards Lifesciences’ Sapien 3 Ultra TAVR [Image courtesy of Edwards Lifesciences]

Jefferies equity research reported that sales of transcatheter aortic valve replacement (TAVR) are better than the previous quarter with flat growth.

Edwards Lifesciences (NYSE:EW) reported among its second-quarter results that TAVR sales had taken a -12% hit for the three months ended June 30, 2020. When the company reported its quarterly results, it noted that it had seen cases of people holding off on heart valve replacement because they are worried about potentially catching COVID-19.

Jefferies currently has Edwards’ TAVR growth ranging from -7.5% to 2.0%, falling roughly in line with the -2% to 0.6% in consensus. According to the analysts’ report, the company’s third-quarter results are looking to fall in the consensus range.

While the third quarter looks to be an improvement over Edwards’…

Read more
  • 0